Background/Aims: Gastric cancer (GC) is one of the most prevalent digestive malignancies.
Introduction
Gastric cancer (GC) is one of the most prevalent digestive malignancies, the fourth most frequent malignancy, and the third leading cause of cancer-associated death worldwide [1] . In China, with 679, 100 new cases and 498, 000 deaths in 2015, both its morbidity and mortality rank second only to lung cancer [2] . Despite advances in early diagnosis and surgical techniques, patients with advanced GC still have a poor prognosis with a 5-year overall survival below 25% [3] . Because multiple factors, including heredity and genetics, strategies aimed at revealing the molecular mechanisms underlying GC is an urgent issue.
MicroRNAs are endogenous, highly conserved, small noncoding RNAs of approximately 19-24 nucleotides in length [5] . They negatively exert a vital role in regulating gene expression, mainly by binding to the 3' untranslated region (3'UTR) of target mRNA at the post-transcriptional level, causing its degradation or translational suppression [6, 7] . miRNAs participate in various biological activities in cells, such as proliferation, migration, invasion, and apoptosis [8] . Many lines of evidence suggest that aberrant expression of miRNA also plays a role in cancer progression by affecting exclusive oncogenes or tumor suppressors [9] [10] [11] .
According to The Cancer Genome Atlas (TCGA) database, miR-592 is abnormally overexpressed in GC tissues compared with adjacent normal tissues. miR-592 is also dysregulated in diverse human cancers [12] [13] [14] [15] [16] , acting as an oncogene in cancers such as colorectal [12, 13] and prostate [14] . In contrast, miR-592 serves as a tumor suppressor in hepatocellular carcinoma [15, 16] . Nevertheless, the potential roles and molecular mechanisms of miR-592 in GC need further investigation.
induced Ras/MAPK signal pathway [17, 18] . As one of four mammalian isoforms, Sprouty2 manifests the highest evolutionary conservation and its loss or dysregulation has been linked to ovarian carcinoma [19] , renal carcinoma [20] , and lung cancer [21] . However, Spry2 also serves as an oncogene driving the epithelial-mesenchymal transition (EMT) in colorectal cancer [22] . In addition, Spry2 plays a suppressive role in GC [23] .
In this study, we investigated the role of miR-592 in GC and hypothesized that Spry2 might be one of the putative direct targets of miR-592 through bioinformatics predictions and experimental validation. Our results indicated that miR-592 overexpression could promote the progression and development of GC by targeting Spry2 through the PI3K/AKT and MAPK/ERK signaling pathways in vitro and in vivo indicate a therapeutic target for GC.
Materials and Methods

Human tissue samples
Human GC tissues and paired adjacent normal tissues were acquired from 70 GC patients who underwent University, China. After resection, all specimens were immediately stored in liquid nitrogen and the relevant Nanjing Medical University Ethics Committees and all patients or relatives signed informed consent.
Cell lines
Human GC cell lines (SGC7901, BGC823, MGC803, and AGS) and human normal gastric mucous epithelium cells (GES-1) were purchased from the American Type Culture Collection (Manassas, VA, USA). RNA extraction and quantitative real-time PCR Total RNA, including miRNA and mRNA, was extracted from cells and tissues with Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Subsequently, we applied PrimeScript RT Reagent (Takara, Japan) to synthesize cDNA for human Spry2. To detect miRNA expression, a poly(A) polymerase was used to polyadenylate and elongate the miRNA, and then an Oligo-dT adaptor with a universal tag sequence on its 5' end was mixed with the decorated RNA. The sequence of the Oligo-dT real-time PCR (qRT-PCR) was performed on a 7500 Real-time PCR System (Applied Biosystems, Carlsbad, CA, USA) with a SYBR Premix Ex Taq Kit (Vazyme, Nanjing, China) to determine the relative expression 5'-ACCTGGCCGT CAGGCAGCTC-3'. All procedures were performed in triplicate and the relative expression was calculated by means of the 2 method.
Western blot assay
Total protein was extracted using RIPA lysis buffer (Beyotime, Shanghai, China) supplemented with and centrifugation at 14, 000 rpm for 15 min at 4°C, the supernatant was collected and mixed with sodium dodecyl sulfate loading buffer. The solution was boiled for 5 min and stored at -20°C. Isolated proteins from cells and tissues were then electrophoresed on 10% sodium dodecyl sulfate polyacrylamide gel primary antibodies (1:1, 000) at 4°C overnight. The next day, after recycling antibodies, the membrane was washed three times with Tris-buffered saline with Tween-20 (TBST) for 15 min each and then incubated with secondary antibodies (1:10, 000) at room temperature for 2 h. After three more washes with TBST, the relative expression levels of the protein were detected via an enhanced chemiluminescence detection system.
Lentivirus construction and cell transfection
To overexpress or knockdown miR-592 in GC cells, commercially available LV2-has-miR-592-mimics vector (miR-592-mimics) and LV2-has-miR-592 inhibitor vector (miR-592-inhibitor) were constructed (GenePharma, Shanghai, China). The LV2 empty vector construct (miR-NC) functioned as a negative control. construct and packing plasmids and then viral particles were collected and the titer determined before the were infected with the lentiviral vectors at the appropriate multiplicity of infection: 20 for SGC7901 cells and 50 for BGC823 cells. Stably transfected cell lines were acquired by using 5 μg/ml puromycin (Sigma, USA) for 1 week. Lentiviral vector containing Spry2 coding sequence (LV-Spry2) and the corresponding negative control (vector) were also made by GenePharma Biotech (Shanghai, China). The synthesized coding sequence of Spry2 was cloned into the vector and used to generate the stable cell lines by the above methods.
Dual-luciferase reporter assay
To determine whether Spry2 is a direct target of miR-592, the 3'UTR sequence of Spry2 mRNA with its full length of 782 nucleotides including wild-type or mutated miR-592 binding sites was synthesized by GeneScript (Nanjing, China Immunohistochemistry then steeped in sodium citrate and 3% hydrogen peroxide for antigen retrieval and to quench endogenous peroxidase activity. Sections were incubated overnight at 4°C with primary antibody. After being washed with phosphate buffered saline (PBS), the slices were incubated with horseradish peroxidase polymerconjugated secondary antibody at 37°C for 1 h, and then stained with 3, 3-diaminobenzidine solution for 3 min to visualize the staining. Hematoxylin was used to counterstain nuclei.
Cell proliferation assay
To examine the proliferation of GC cells, 1 × 10 3 cells/well were seeded in 96-well plates and cultured manufacturer's instructions with 100 μl RPMI-1640 and incubated at 37°C for 2 h. Absorbance was then measured at 450 nm, which obtains the appropriate OD value for evaluating cell numbers.
Population doubling time determination
plates with 1 × 10 3 absorbance was measured at a set point every day. Cell proliferation was determined via characterization of the logarithmic phase of growth with the population doubling time (PDT): PDT = (log2 × (t 2 -t 1 ))/(logN 2 -logN 1 ), where N 2 is the number of cells harvested at the end of the growth period, N 1 indicates the initial cell number, and (t 2 -t 1 and the experiments were performed in triplicate.
Colony formation assay
Stably transfected GC cells were seeded in 6-well plates (500 cells/well) and cultured in an incubator with 5% CO 2 counted.
Transwell assay
4 cells were placed in the top chamber in 200 μl 1% crystal violet for 20 min. The cells on the upper layer of the chambers that could not migrate to the opposite surface were carefully removed with a cotton swab, whereas the cells on the lower surface were added onto the plate surface and the cells were incubated for 2 h and then assessed as indicated above. suspension were washed several times in PBS and adherent cells were cultured in serum-free medium. After the separation distance between wound sides was calculated. The experiments were performed in triplicate.
In vivo tumorigenicity
University. All animal experiments were approved and consistent with the Institutional Animal Care and Use Committee of Nanjing Medical University. The mice were randomly divided into six groups. Stably miR-592-mimics, BGC823-miR-592-inhibitor, and BGC823-NC) were suspended in PBS and inoculated 6 measured with Vernier calipers every 4 days for 3 weeks until the mice were euthanized and the relative tumor volume doubling time was determined using the PDT formula introduced above. The implanted 2 width.
Statistical analysis
Data from three independent experiments are shown as the mean ± standard deviation. Using SPSS software version 19.0, differences between two groups were determined by a two-tailed Student's t test.
2 tests. Analysis of variance was used to compare treated and control groups. P
Results
miR-592 is upregulated in GC tissues and cells
According to the TCGA database, which includes 413 primary GC tissues and 43 adjacent verify whether miR-592 was dysregulated in GC tissues, 70 pairs of GC tissues and adjacent normal tissues were collected to determine the relative expression of miR-592 using qRTincreased in 51 of the paired cases and decreased in the remaining 19 pairs compared with the corresponding adjacent tissues. In addition, the expression of miR-592 in normal GES-1 and GC cell lines (SGC7901, MGC803, BGC823, and AGS) was further examined with qRTresults were consistent with the data in TCGA and indicated that the expression of miR-592 was upregulated in both GC tissues and cells.
Next, we analyzed the correlation between miR-592 expression and clinicopathologic features. GC patients (n = 70) were divided into two groups based on the relative expression of miR-592 (whether higher or not than the mean expression): the high miR-592 expression group (n = 33) and the low miR-592 expression group (n = 37). As shown in Table 1 , high miR-592 expression was associated with tumor size, histological type, and lymph node development and progression of GC. in various GC cells determined with qRT-PCR (relatively low in SGC7901 and relatively high in BGC823). In addition, the two cell lines were stably transfected with miR-592-mimics or the relative expression of miR-592 was markedly increased and decreased in SGC7901 cells transfected with miR-592-mimics and -inhibitor, respectively, versus the negative control groups. The same results were achieved in the BGC823 cell line. A CCK8 assay was conducted to probe the effect of miR-592 on GC cell proliferation. Ectopic expression of miR-592 boosted the proliferation rate of both SGC7901 and BGC823 cell lines compared with control groups and the opposite effects were detected in the with the control group, the miR-592-mimics group showed a shortened PDT and the miR-592-inhibitor group had a longer PDT. Additionally, a colony formation assay was carried were consistent with the CCK8 assay and showed that upregulated expression of miR-592 promoted the colony formation ability of the two chosen cell lines versus the control group in vitro studies indicated that the expression of miR-592 was positively correlated with the proliferation of GC, which means that overexpressed miR-592 could facilitate the proliferation of GC, with miR-592 knockdown having the opposite effects.
miR-592 facilitates the proliferation of GC
BGC823 cells for biological function experiments in line with the miR-592 expression results
miR-592 promotes GC migration and invasion
To further validate the oncogenic role of miR-592 in GC cells, wound-healing and Transwell assays were performed. In the wound-healing assay, overexpression of miR-592 increased the migration rate of both types of cells at two set time points. In contrast, reduced assay, when miR-592 was upregulated, the number of migrated cells was dramatically increased, and the opposite results were observed when miR-592 was downregulated at increased when the chamber was coated with Matrigel, compared with the negative control, results demonstrated that miR-592 promotes the migration and invasion of GC cells in vitro. with miR-592-mimics and miR-592-inhibitor lentivirus. * P <0.05, ** P <0.01, *** P <0.001. The data expressed as the mean±SD. Moreover, qRT-PCR analysis revealed upregulated miR-592 expression in the miR-592-mimics group compared with the control group, but reduced expression in the miRTaken together, miR-592 has a positive effect on the tumorigenicity of GC in vivo.
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Spry2 is a predicted target of miR-592
TargetScan (http://www. t a r g e t s c a n . o r g / v e r t _ 7 1 / ) , miRNAMap ( (https://cm.jefferson. edu/rna22/Precomputed/) were applied to predict the targets of miR-592. According to the intersection of the three computational prediction results, we found that Spry2, a known tumor suppressor, was a potential target of miR-592.
Spry2 is downregulated in GC tissues and cells
To explore the relationship between miR-592 and Spry2, we determined the expression compared with the paired adjacent normal tissues, the relative expression of miR-592 was clearly reduced in primary tumor tissues. In addition, we examined the Spry2 protein immunohistochemical expression of Spry2 was lower in GC tissues than in the adjacent mRNA and protein levels was distinctly lower in GC cells than in GES-1 cells. In addition, we conducted a correlation analysis between the Spry2 expression level and the clinicopathologic characteristics of GC patients (Table 1) . Low Spry2 expression was correlated with tumor size, histological type, and lymph node metastasis. All of these results suggested that Spry2 might be a target of miR-592 in GC and play a role in tumor inhibition. 3'UTR sequences (the former containing the original binging site and the latter containing Spry2 3'UTR were cotransfected into SGC7901 and BGC823 cells, with the results indicating that overexpression of miR-592 could decrease luciferase activity compared with the control group. However, there was no evident change in luciferase activity in the same cells
Spry2 is a direct target of miR-592 in GC
miR-592 represses Spry2 protein expression via mRNA degradation
To study the explicit mechanism by which miR-592 regulated Spry2, we performed western blot to analyze Spry2 protein levels. In contrast to the control, Spry2 protein levels in SGC7901 and BGC823 cells were clearly reduced after transfection with miR-592-transfection with miR-592-mimics and miR-592-inhibitor, qRT-PCR was used to determine whether there was a difference in Spry2 mRNA levels in the two cell lines compared with the transfected with miR-592-mimics was lower than in the control, and the inverse result was obtained with miR-592-inhibitor. The relative protein expression of Spry2 from xenografted 
miR-592 promotes GC cell proliferation, migration, and invasion by targeting Spry2
invasion in GC cells and suppressed Spry2 protein expression by directly binding to the 3'UTR of Spry2 and triggering its mRNA degradation. In contrast, miR-592 downregulation had the opposite effects. To further determine whether miR-592 promoted the progression Through CCK8, PDT, colony formation, wound-healing, and Transwell assays, we found that conjunction with the above assays, we performed the appropriate rescue experiments and demonstrated that ectopic expression of Spry2 could reverse the promotion of proliferation, migration, and invasion induced by miR-592 overexpression in SGC7901 cells. The same 
Overexpression of miR-592 induces the EMT via Spry2
The EMT is a vital biological process in which malignant cells acquire migratory and in GC cells by targeting Spry2. Hence, we wondered if miR-592 might play a role in the EMT of GC cells and thus used western blotting to examine the expression of characteristic 6A, compared with miR-NC, SGC7901 and BGC823 cells transfected with miR-592-mimics revealed decreased expression of E-cadherin and increased expression of vimentin and in GC cells.
miR-592 promotes the PI3K/AKT and MAPK/ERK signaling pathway in GC cells by targeting Spry2
The classic PI3K/AKT and MAPK/ERK signaling pathways modulate the progression of various cancers by affecting their proliferation, migration, and invasion [24] [25] [26] . Spry2 signaling pathways [27] [28] [29] . Therefore, we examined the expression of ERK, p-ERK, AKT, and p-AKT with western blot to determine whether miR-592 participates in the activation of PI3K/ AKT and MAPK/ERK signaling pathways. The potential target of miR-592 was predicted by bioinformatics analysis. Of the putative targets, Spry2, which has three homologues, drew our attention. The Spry family (spry1-4) tracheal branching morphogenesis [17] . It was also noted for regulating the receptor tyrosine kinase (RTK)-mediated MAPK/ERK signaling pathway because it has a cysteine-rich domain activation of RAS/ERK [23] . In addition, Spry2 can be targeted and modulated by several miRNAs. Shukla et al. reported that Spry2 was suppressed by miR-21 and negatively regulated BCR-mediated MAPK-ERK signaling in chronic lymphocytic leukemia [36] . miR-27b may promote the migration and invasion of hepatocellular carcinoma cells, at least partially by suppressing Spry2 expression [37] .
showing that Spry2 expression was much lower in GC tissues than in paired normal tissues and GES-1 cells. By analyzing clinicopathological characteristics, we determined that Spry2 expression was correlated with tumor size, histological type, and lymph node metastasis. In addition, dual-luciferase reporter assays showed that miR-592 suppressed Spry2 by directly binding to its 3'UTR and that overexpressed miR-592 could suppress Spry2 expression by degrading Spry2 mRNA. In addition, restoration of Spry2 partially counteracted the inductive effects of miR-592-mimics on proliferation, migration, and invasion. In summary, our study demonstrated the ability of miR-592 to promote GC in a manner that is modulated by Spry2 inhibition.
The EMT, the biological process by which epithelial cells are transformed into stromal EMT is characterized by a series of reversible molecular and phenotypic alterations and increased cell motility that promote the biological aggressiveness of malignant cells, such as invasion and metastasis [38, 39] . Recent accumulating evidence has indicated that miRNAs [23] . Loss of Spry2 can also activate the PI3K/AKT pathway the two signaling pathways could be illustrated by one potential molecular mechanism: Spry proteins interact with GRB2, which is the SH2/SH3 domain-containing adapter protein, and can link to and activate the RTK implicated in both pathways. Accordingly, the gain or loss of Spry2 allows regulation of these two classic oncogenic pathways [27, 48] . In the present study, miR-592 was shown to modulate the PI3K/AKT and MAPK/ERK signaling pathways by directly targeting Spry2. Overexpressed miR-592 promoted the phosphorylation and activation of AKT and ERK while downregulated miR-592 exerted the opposite effect.
Although it seems that the molecular mechanisms exploited by miRNAs are quite constitute an miRNA cluster, which regulates the common target and the signaling pathways.
cell pathogenicity [49] . Methylation of miRNA promoters can itself also account for the aberrant expression of miRNA and be associated with cancer susceptibility [50] . In addition, miR-122 can downregulate the expression of miR-21 by directly binding to the pri-miR-21
suggesting that the regulation of miR-592 is its diverse and complicated. Therapies based on miRNAs have gradually moved from the theoretical realm to clinical application. A mimic of miR-34, which acts as a tumor suppressor, has reached phase I clinical trials for the treatment of cancer. In addition, anti-miRNAs targeted at miR-122 have reached the feasibility and safety of an miR-592-based therapeutic is urgently needed. miR-592 promotes proliferation, migration, and invasion and induces the EMT through the miRNA may control and target multiple genes and one single gene can also be regulated by out the potential role of other genes targeted by miR-592 and related signaling pathways in these processes, which could further explain the potential mechanisms. Thus, protocol optimization and further study are required. In summary, our study showed that miR-592 was correlated with tumor size, histological type, and lymph node metastasis and that it promoted proliferation, migration, invasion, and the EMT by inhibiting Spry2-mediated PI3K/AKT and MAPK/ERK signaling pathways. These
